Allogene Therapeutics, Inc.
ALLO
NASDAQ·Healthcare·Biotechnology·Mkt cap $680.0M
$1.97
▼ -0.51%
P/E
-2.94
Mkt Cap
$680.0M
52-Wk Range
$1.04–$4.46
52-Week Range
$1.04 - $4.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 72.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Off-the-shelf allogeneic CAR T platform eliminating patient-specific manufacturing delays and costs
- Strategic partnerships with Pfizer, Servier, and Cellectis providing capital, expertise, and commercialization reach
- Collaboration with MD Anderson Cancer Center enhancing clinical development and credibility
- Diversified pipeline across multiple cancer indications reducing development risk
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Emerging player in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+6.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ALLO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 12, 2026
Reported EPS of -$0.13 vs -$0.17 consensus (+24.1% surprise). Revenue of $4.6M vs $2.5K expected (+185500.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+24.1%
Revenue trend · last 8Q
—
—
-100%
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
10 analysts · 70% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
70%
Hold
30%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 17, 2026
vs Industry
How ALLO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related